Brief: Annexon Outlines Global Registrational Program For Anx007 In Geographic Atrophy With FDA Alignment On Vision Preservation As Primary Endpoint

Annexon

20/12/2023 22:55

Dec 20 (Reuters) - Annexon Inc  ANNX.O :
    * ANNEXON OUTLINES GLOBAL REGISTRATIONAL PROGRAM FOR ANX007
IN
GEOGRAPHIC ATROPHY WITH FDA ALIGNMENT ON VISION PRESERVATION AS
PRIMARY ENDPOINT
    * ANNEXON INC - ARCHER II, A GLOBAL SHAM-CONTROLLED TRIAL
SUPPORTING A POTENTIALLY FASTER PATH TO REGISTRATION, EXPECTED
TO INITIATE IN MID-2024
    * ANNEXON INC - ARROW EXPECTED TO INITIATE IN LATE 2024
    * ANNEXON INC-  WILL SEEK FEEDBACK FROM EMA ON PIVOTAL PHASE
3
PROGRAM IN FIRST HALF OF 2024 FOR ARROW TRIAL

Source text for Eikon:  ID:nGNX4kC6Hz 
Further company coverage:  ANNX.O 

 ((Reuters.Briefs@thomsonreuters.com;))